The 6 minute walking test in chronic heart failure: indications, interpretation and limitations from a review of the literature

Transcription

1 The European Journal of Heart Failure 6 (2004) Review The 6 minute walking test in chronic heart failure: indications, interpretation and limitations from a review of the literature Pompilio Faggiano a, *, Antonio D Aloia b, Anna Gualeni c, Loretta Brentana d, Livio Dei Cas d a Unità Operativa di Policardiografia, Spedali Civili, Via Trainini 14, Brescia, Italy b Unità Operativa di Cardiologia, Spedali Civili, Brescia, Italy c Unità Operativa di Cardiologia, Ospedale S.Orsola-Fatebenefratelli, Brescia, Italy d Cattedra di Cardiologia, Università di Brescia, Italy Received 22 January 2003; received in revised form 4 November 2003; accepted 26 November 2003 Available online 5 June Contents 1. Introduction Determinants of the 6MWT Normal values of the 6MWT and use of a reference equation Maximal or sub-maximal test The problem of reproducibility The prognostic significance of the 6MWT Evaluation of the effectiveness of therapy The American Thoracic Society guidelines References Introduction The 6 min walking test (6MWT) was first used to evaluate patients with chronic respiratory diseases such as chronic obstructive pulmonary disease and respiratory failure. The test attracted the attention of cardiologists because it was easy to perform and interpret. For this reason its role in measuring functional limitation, in evaluating the effects of therapy and in the prognostic stratification of patients with chronic heart failure has been widely investigated. The 6MWT is a simple test which does not require expensive equipment or advanced training for technicians. The test involves asking the patient to walk the longest distance possible in a set interval of 6 min, through a walking course (corridor) preferably 30-m long. The patient can stop or slow down at any time and then resume walking, * Corresponding author. Tel.: ; fax: address: faggiano@numerica.it (P. Faggiano). depending on his/her degree of fatigue. Even though other parameters can be monitored during the test, such as arterial pressure and/or heart rate, the number of times the patient has to stop during the test, the speed of walking or even changes in respiratory gases (measured using a portable instrument) and oxygen saturation, the distance walked in 6 min is the parameter usually taken into consideration in clinical practice and also the one that has proven to be most useful in nearly all clinical studies. The first studies on the use of the 6MWT in chronic heart failure were published just over 15 years ago. Guyatt [1] in 1985 and Lipkin [2] in 1986 reported that the distance covered during the 6MWT can identify the most compromised patients and differentiate them from the less severe cases (based on the NYHA classification). The test also showed a good correlation with objective measures of effort tolerance, such as exercise duration and oxygen uptake at the peak of exercise. Furthermore, patients preferred the 6 min walking test to the conventional exercise test because it was similar to the activities of daily living. A few years later Bittner et al. reported that the distance walked during the 6MWT was a strong and /$ - see front matter D 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved. doi: /j.ejheart

2 688 P. Faggiano et al. / The European Journal of Heart Failure 6 (2004) independent predictor of morbidity and mortality in patients with left ventricular dysfunction [3]. A great number of studies on the 6MWT have been published in the last 10 years, exploring both its physiopathologic determinants and its practical applications. The aim of this paper is to illustrate how the 6MWT can be used in patients with heart failure, based on a review of the existing literature and the guidelines that have recently been published. 2. Determinants of the 6MWT As previously documented, peak exercise oxygen uptake (VO 2 peak), even for the 6MWT has a poor correlation with the haemodynamic indices recorded at rest. In two studies in which the relation between the distance walked and different haemodynamic and ventricular functional indices was evaluated in patients with chronic heart failure, only right ventricular ejection fraction showed a small but significant correlation with 6MWT [4,5]. Several non-cardiovascular parameters showed a correlation with the 6MWT and were good predictors of the distance walked [6 8]. Amongst these, the indexes of muscular strength, of postural balance and of reaction time, mood and general health (the latter was evaluated using specific questionnaires) were significantly correlated to the 6MWT. The combination of these variables was found to be responsible for 52.5% [7] and 69% [6], respectively, of the variance of the distance walked during the walking test in two studies carried out on healthy subjects over 62 years. Based on these results, the 6MWT can be considered as a global performance test rather than just a test of cardiovascular performance [6,7]. It is thus suggested that the 6MWT may have a wider use than just the evaluation of cardiovascular adaptation to effort, especially in elderly patients. Of interest, the maximum distance walked during the walking test has been shown to correlate significantly with some anthropometric variables, such as gender(less in women), age and weight (inverse relationship), height (direct relationship) [9 11]. Therefore, these factors should be taken into consideration when interpreting the results of a single measurement made to determine functional status. 3. Normal values of the 6MWT and use of a reference equation The maximum distance walked during the 6MWT has been used in heart failure to identify patients with a greater functional impairment and with a worse prognosis from those that are less compromised. Quartiles of distance, derived from the distribution in a study population, such as SOLVD [3], have generally been employed for this. The lack of 6MWT data in healthy people has, up until now, Fig. 1. Relation between distance walked during the 6-min walk test (mean values and confidence intervals) and age in a group of healthy subjects. See text for details. Modified from Enright et al. [9]. limited its use in identifying whether there is a reduction in functional capacity and how severe it is. Recently, 6MWT values in relatively large populations of healthy people of different ages have been published [9 12]. It has thus been possible to define normal levels (mean values, confidence intervals and lower limits of normal) and predictive equations have been introduced [9,13] taking into account anthropometric variables (gender, age, weight, height) correlated to the walking test (Fig. 1, Table 1). Analysing the values reported in Fig. 1 it could be considered that the same distance of 250 m walked during the 6MWT may indicate a lower limit of normal functional capacity in an 80-year-old man and a severe reduction in effort tolerance in a 45-year-old man, with obvious clinical implications. It has thus been suggested that the results of the test should be expressed not only as an absolute value (the distance walked in meters), which can be useful for example in the same patient when evaluating the effects of therapeutic interventions, but also as a percentage of the predicted value, as is done for other functional capacity indexes, for example the VO 2 peak [14]. 4. Maximal or sub-maximal test Because of some of the intrinsic features of the test, such as execution time (max 6 min), simplicity (walking on a flat surface), greater acceptance by patients compared to a conventional exercise test (symptom-limited), the 6MWT has come to be considered a sub-maximal test. The indications to perform a 6MWT could thus differ from those of a maximal exercise test. However, in most studies the longest distance walked during the 6MWT has shown a medium-tohigh correlation with the VO 2 measured at the peak of maximal exercise test. It has also been shown that the oxygen uptake at the end of the 6MWT, measured using portable instruments, shows a close correlation with the VO 2 peak [15 17]. In some patients, the VO 2 at the end of the walking test was even greater than the VO 2 peak. Consequently, the 6MWT does not seem to have the features of a sub-maximal test. It could instead be used to assess the

3 P. Faggiano et al. / The European Journal of Heart Failure 6 (2004) Table 1 Reference equation for the distance walked during the 6-min walking test in adult healthy subjects Men 6MWD=(7.57 height cm ) (1.76 weight kg ) (5.02 age) 309 m Alternate equation using the body mass index (BMI,expressed in kg/m 2 ): 6MWD = 1140 m (5.61 BMI) (6.94 age) With both equations subtract 153 m to obtain the lower limit of normal Women 6MWD=(2.11 height cm ) (2.29 weight kg ) (5.78 age) m Alternate equation using the body mass index (BMI,expressed in kg/m 2 ): 6MWD = 1017 m (6.24 BMI) (5.83 age) With both equations subtract 139 m to obtain the lower limit of normal Modified from Enright et al. Am J Respir Crit Care Med 1998; 158: maximal functional capacity in patients with heart failure [16,17]. 5. The problem of reproducibility The degree of reproducibility of a diagnostic or prognostic indicator is one of the factors that can determine its use in clinical practice. The longest distance walked during the 6MWT seems to indicate the effect of a learning curve, because it tends to increase when the test is repeated after a short period of time. It then seems to remain stable from the second/third test onwards. Encouragement given during the test also seems to have a great effect [18], thus indicating the need to use the same protocol during serial measurements [14]. Opasich et al. investigated the problem of reproducibility of the 6MWT in a large group of patients with heart failure [19]. The authors confirmed that the distance walked tended to increase in the individual patient when two tests were performed 30 min apart ( + 19 m). It has also been calculated that the minimum variation in the walked distance that can be considered an expression of a real variation of functional capacity is approximately 10% of the average of two consecutive tests [19]. As a consequence, when the 6MWT is used as an end-point in intervention studies the clinical relevance of the results must be considered cautiously, if the variation in distance is less than 10% in individuals, even though the results are statistically significant. 6. The prognostic significance of the 6MWT Many different studies have investigated whether the distance walked during the walking test is a prognostic indicator in chronic heart failure patients. Lower levels of functional capacity (a distance < 300 m during 6MWT) have proven to be predictive of mortality (total or cardiovascular) and morbidity (hospitalization for worsening heart failure) both in patients with asymptomatic left ventricular systolic dysfunction and in those with mild-moderate [3,4,20] and advanced heart failure [21,22]. In the SOLVD study, total mortality was 10.23% in subjects with a 6MWT < 300 m and 2.99% in subjects with a 6MWT z m [3]. The difference between the two groups is even more evident when considering hospitalizations for heart failure (22.16% vs. 1.99%). In patients with advanced heart failure that are being evaluated for heart transplantation, the walking test has proven able to predict short term (6 month) mortality or the need for inotropic support, whereas the VO 2 peak has been shown to be a better mid-long term prognostic indicator [21]. In some studies, the distance walked during the 6MWT was not an independent prognostic indicator when it was included in models that also considered the VO 2 peak [5,23]. On one hand, this confirms that the information given by the 6MWT is very similar to that of the cardiopulmonary exercise test and on the other it seems to indicate that the prognostic relevance of the distance walked is very low or absent when the VO 2 peak Fig. 2. Effects of therapeutic interventions on the 6MWT. Left: the dashed line shows the variations of distance walked during 6MWT observed in patients with stable heart failure in whom drug dosages were unchanged in short-term; while, the continuous line shows the behavior of distance walked in heart failure patients in whom dosages of diuretics and vasodilators have been gradually increased as tolerated. Mean time interval between the repeated 6MWT was days in the two groups. Adapted from Gualeni et al. [26]. Right: variation in distance walked during the 6MWT at baseline, after three weeks of physical training and after three weeks of activity restriction in a group of patients with stable heart failure. Adapted from Meyer et al. [27]. See text for details.

4 690 P. Faggiano et al. / The European Journal of Heart Failure 6 (2004) Table 2 American Thoracic Society statement: guidelines for the 6-min walk test Indications Evaluation of functional capacity Cystic fibrosis Peripheral vascular disease Older subjects Evaluation of effects of therapeutic interventions Lung transplantation Lung resection Lung volume reduction surgery Pulmonary rehabilitation Pulmonary hypertension Prognostic stratification (mortality and morbidity) Primary pulmonary hypertension Modified from Am J Respir Crit Care Med 2002; 106; is available. However, it should be emphasized that the cardiopulmonary exercise test is not frequently used in chronic heart failure patients for several reasons, including the limited availability of equipment and the inability of patients to perform a maximal effort test [24,25]. Furthermore, in studies using the 6MWT for prognostic stratification attention has been concentrated on young, male patients, whose clinical picture is determined by a moderate-to-severe left ventricular systolic dysfunction. There are no data on the prognostic significance of the 6MWT in elderly patients, in women and in patients with left ventricular diastolic dysfunction, who are rarely included in randomized trials. 7. Evaluation of the effectiveness of therapy The 6MWT has been used in many studies to assess the effect of therapeutic interventions in patients with heart failure. The variations in the distance walked during the walking test have been reported to identify the short term effects of the tailoring of standard pharmacological therapy (diuretics, vasodilators, digitalis) and of a personalized program of physical training [26,27] (Fig. 2). The 6MWT has also been employed in studies assessing the effectiveness of new drugs, such as beta-blockers, in addition to standard therapy [28], the use of intravenous inotropic drugs [29] and prostaglandin analogues [30,31]. The distance walked during the walking test has demonstrated the effects of ventricular assistance devices [16] on functional capacity and more recently the effect of ventricular resynchronization techniques [32,33]. The changes in the 6MWT after therapeutic intervention reported in many studies may show large positive or negative variations (from 5 10 to m and even more). The meaning of this variance must always be interpreted, both in the single patient and in the trial population, bearing in mind current knowledge on test reproducibility and its capacity to identify real changes in the clinical picture and prognosis (responsiveness). Furthermore, the correct way to express changes in 6 MWT for clinical purposes (absolute value, percentage change from baseline or percentage change of predicted value) is not yet known. 8. The American Thoracic Society guidelines Based on the data presented, the 6MWT appears to be a very useful test to evaluate chronic heart failure patients, however, the above-mentioned limitations (and others that may appear once the test is more widely used) must always be considered. The recently published American Thoracic Society Guidelines for the 6MWT [14] support the standardized approach to the 6MWT described in this review and recommend the use of the 6MWT not only in subjects with lung disease but also in those with heart failure as a onetime measure of functional status and for the evaluation of the effects of therapy and prognostic stratification (Table 2). These guidelines, based on a comprehensive Medline literature, other than reviewing the most common indications and limitations of the test, also provide a detailed description of practical aspects to perform a standardized and reproducible test in the clinical setting. References [1] Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-min walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132: [2] Lipkin DP, Scriven AJ, Crake T, Poole-Wilson PA. Six minute walking test for assessing exercise capacity in chronic heart failure. Br Med J 1986;292: [3] Bittner V, Weiner D, Yusuf S, et al. Prediction of mortality and morbility with a 6-min walk test in patients with left ventricular dysfunction. J Am Med Assoc 1993;270: [4] Zugck C, Kruger C, Durr S, et al. Is the 6-min walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy? Eur Heart J 2000;21: [5] Opasich C, Pinna GD, Mazza A, et al. Six-minute walking performance in patients with moderate-to-severe heart failure. It is a useful indicator in clinical practice? Eur Heart J 2001;22: [6] Harada ND, Chiu V, Stewart AL. Mobility-related function in older adults: assessment with a 6-min walk test. Arch Phys Med Rehab 1999;80: [7] Lord SR, Menz HB. Physiologic, psychologic and health predictors of 6-min walk performance in older people. Arch Phys Med Rehab 2002;83: [8] O Keeffe ST, Lye M, Donnellan C, Carmichael DN. Reproducibility and responsiveness of quality of life assessment and 6-min walk test in elderly heart failure patients. Heart 1998;80:

5 P. Faggiano et al. / The European Journal of Heart Failure 6 (2004) [9] Enright PL, Sherrill DL. Reference equations for the 6-min walk in healthy adultsm. Am J Respir Crit Care Med 1998;158: [10] Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J 1999;14: [11] Steffen TM, Hacker TA, Mollinger L. Age- and gender-related test performance in community-dwelling elderly people: 6-min walk test, Berg balance scale, timed up and go test and gait speeds. Physical Therapy 2002;82: [12] Federmann M, Fleisch D, Roos M, et al. Normal values and determinants of the 6-min walking test. 48th Annual Scientific Session American College of Cardiology, 1999 (abstr). [13] Gibbons WJ, Fruchter N, Sloan S, Levy RD. Reference values for a multiple repetition 6-min walk test in healthy adults older than 20 years. J Cardiopulm Rehab 2001;21: [14] ATS statement: guidelines for the 6-min walking test. Am J Respir Crit Care Med 2002;166: [15] Riley M, McParland J, Stanford CF, Nicholls DP. Oxygen consumption during corridor walk testing in chronic cardiac failure. Eur Heart J 1992;13: [16] Foray A, Williams D, Reemtsma K, Oz M, Mancini D. Assessment of submaximal exercise capacity in patients with left ventricular assist device. Circulation 1996;94(Suppl II):II [17] Faggiano P, D Aloia A, Gualeni A, Lavatelli A, Giordano A. Assessment of oxygen uptake during the 6-min walking test in patients with heart failure: preliminary experience using a portable device. Am Heart J 1997;134: [18] Guyatt GH, Pugsley SO, Sullivan MJ, et al. Effects of encouragement on walking test performance. Thorax 1984;39: [19] Opasich C, Pinna GD, Mazza A, et al. Reproducibility of the 6-min walking test in patients with chronic congestive heart failure. Am J Cardiol 1998;81: [20] Roul G, Germain P, Bareiss P. Does the 6-min walk test predict the prognosis in patients with NYHA class II or III chronic heart failure? Am Heart J 1998;136: [21] Cahalin LP, Mathier M, Semigran MJ, Dec GW, DiSalvo TG. The 6-min walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest 1996;110: [22] Shah MR, Hasselblad V, Gheorghiade M, et al. Prognostic usefulness of the 6-min walk in patients with advanced congestive heart failure secondary to ischemic or non-ischemic cardiomyopathy. Am J Cardiol 2001;88: [23] Lucas C, Stevenson LW, Johnson W, et al. The 6-min walk and peak oxygen consumption in advanced heart failure: aerobic capacity and survival. Am Heart J 1999;138: [24] Demers C, McKelvie RS, Negassa A, Yusuf S, for the RESOLVD Pilot Study Investigators. Reliability, validity and responsiveness of the 6-min walk test in patients with heart failure. Am Heart J 2001;142: [25] Seosi investigators. Survey on heart failure in Italian hospital cardiology units. Results of the Seosi study. Eur Heart J 1997;18: [26] Gualeni A, D Aloia A, Gentilini A, Pagani M, Giordano A, Faggiano P. Effects of maximally tolerated oral therapy on the 6-min walking test in patients with chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1998;81: [27] Meyer K, Schwaibold M, Westbrook S, et al. Effects of exercise training and activity restriction on 6-min walking test performance in patients with chronic heart failure. Am Heart J 1997;133: [28] Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92: [29] Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE Multicenter trial. Am Heart J 1999;138: [30] Califf RM, Adams KF, McKenna WJ, et al. A randomised controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134: [31] Galiè N, Humbert M, Vachiery JL, et al. Effect of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double blind, placebo-controlled trial. J Am Coll Cardiol 2002;39: [32] Cazeau S, Leclercq C, Lavergne T, et al., for The Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effect of Multisite Biventricular Pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344: [33] Abraham WT, Fisher WGG, Smith AL, et al., for The MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346: